Proprietary AI analyst is now available

Accuray Valuation Multiples

Discover revenue and EBITDA valuation multiples for Accuray and similar public comparables like Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice and more.

Accuray Overview

About Accuray

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.


Founded

1990

HQ

United States

Employees

990

Financials (LTM)

Revenue: $410M
EBITDA: $2M

EV

$184M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Accuray Financials

Accuray reported last 12-month revenue of $410M and EBITDA of $2M.

In the same LTM period, Accuray generated $106M in gross profit, $2M in EBITDA, and had net loss of ($38M).

Revenue (LTM)


Accuray P&L

In the most recent fiscal year, Accuray reported revenue of $459M and EBITDA of $28M.

Accuray is unprofitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 6%, and net margin of (0%).

See analyst estimates for Accuray
LTMLast FY202320242025202620272028
Revenue$410M$459M$447M$453M$433M
Gross Profit$106M$147M$148M$145M$125M
Gross Margin26%32%33%32%29%
EBITDA$2M$28M$7M$13M$11M
EBITDA Margin1%6%2%3%2%
EBIT Margin(7%)2%0%1%(2%)
Net Profit($38M)($2M)($12M)($9M)($21M)
Net Margin(9%)(0%)(3%)(2%)(5%)
Net Debt-$79M---

Financial data powered by Morningstar, Inc.

Accuray Stock Performance

Accuray has current market cap of $39M, and enterprise value of $184M.

Market Cap Evolution


Accuray's stock price is $0.33.

Accuray share price decreased by 14.4% in the last 30 days, and by 76.0% in the last year.

Accuray has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Accuray
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$184M$39M-1.3%-14.4%-15.2%-76.0%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Accuray Valuation Multiples

Accuray trades at 0.4x EV/Revenue multiple, and 75.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Accuray

EV / Revenue (LTM)


Accuray Financial Valuation Multiples

As of June 11, 2026, Accuray has market cap of $39M and EV of $184M.

Accuray has a P/E ratio of (1.0x).

LTMLast FY202320242025202620272028
EV/Revenue0.4x0.4x0.4x0.4x0.4x
EV/EBITDA75.8x6.5x26.1x14.1x17.3x
EV/EBIT(6.9x)23.4x127.2x44.0x(17.7x)
EV/Gross Profit1.7x1.2x1.2x1.3x1.5x
P/E(1.0x)(24.6x)(3.2x)(4.6x)(1.9x)
EV/FCF-(32.4x)(29.0x)(17.3x)(32.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Accuray Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Accuray Margins & Growth Rates

Accuray decreased revenue by 11% and EBITDA by 96% in the last fiscal year.

In the most recent fiscal year, Accuray reported gross margin of 32%, EBITDA margin of 6%, and net margin of (0%).

See estimated margins and future growth rates for Accuray

Accuray Margins

Last FY202420252026202720282029
Gross Margin32%32%29%27%
EBITDA Margin6%3%2%3%
EBIT Margin2%1%(2%)(5%)
Net Margin(0%)(2%)(5%)(7%)
FCF Margin(1%)(2%)(1%)-

Accuray Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(11%)1%(4%)(5%)
Gross Profit Growth(30%)(2%)(14%)(11%)
EBITDA Growth(96%)84%(18%)5%
EBIT Growth(465%)189%(349%)79%
Net Profit Growth2436%(31%)145%43%
FCF Growth-67%(46%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Accuray Operational KPIs

Accuray's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.

Accuray's Rule of 40 is (3%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Accuray's Rule of X is (11%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Accuray
LTMLast FY202320242025202620272028
Rule of 401%(3%)---
Bessemer Rule of X2%(11%)---
Revenue per Employee-$0.5M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue9%9%10%9%9%
G&A Expenses to Revenue15%10%11%11%12%
R&D Expenses to Revenue10%10%12%11%10%
Opex to Revenue-30%33%31%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Accuray Competitors

Accuray competitors include Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice, Abingdon Health, Q-linea, Optomed, Baird Medical Investment, Diagnostic Medical Systems and Nutriband.

Most Accuray public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Mauna Kea Technologies5.0x5.1x3.2x(13.2x)
Luna Innovations----
RenovoRx23.3x12.8x(2.1x)-
Mentice1.2x1.1x77.1x26.7x
Abingdon Health3.2x2.3x(10.7x)(25.3x)
Q-linea12.5x-(0.9x)-
Optomed1.6x1.5x(7.6x)(10.9x)
Baird Medical Investment2.7x-(2.5x)-

This data is available for Pro users. Sign up to see all Accuray competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Accuray

When was Accuray founded?Accuray was founded in 1990.
Where is Accuray headquartered?Accuray is headquartered in United States.
How many employees does Accuray have?As of today, Accuray has over 990 employees.
Who is the CEO of Accuray?Accuray's CEO is Stephen R. LaNeve.
Is Accuray publicly listed?Yes, Accuray is a public company listed on Nasdaq.
What is the stock symbol of Accuray?Accuray trades under ARAY ticker.
When did Accuray go public?Accuray went public in 2007.
Who are competitors of Accuray?Accuray main competitors include Mauna Kea Technologies, Luna Innovations, RenovoRx, Mentice, Abingdon Health, Q-linea, Optomed, Baird Medical Investment, Diagnostic Medical Systems, Nutriband.
What is the current market cap of Accuray?Accuray's current market cap is $39M.
What is the current revenue of Accuray?Accuray's last 12 months revenue is $410M.
What is the current revenue growth of Accuray?Accuray revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of Accuray?Current revenue multiple of Accuray is 0.4x.
What is the current EBITDA of Accuray?Accuray's last 12 months EBITDA is $2M.
What is Accuray's EBITDA margin?Accuray's last 12 months EBITDA margin is 1%.
What is the current EV/EBITDA multiple of Accuray?Current EBITDA multiple of Accuray is 75.8x.
How many companies Accuray has acquired to date?Accuray hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Accuray has invested to date?Accuray hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Accuray

Lists including Accuray

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial